Table 3.
Overall survival and disease-free survival of patients after neoadjuvant chemotherapy and surgery versus upfront surgery
|
Ref.
|
Overall survival
|
P value
|
Disease-free survival
|
P value
|
||
|
NAT
|
US
|
NAT
|
US
|
|||
| Ahn et al[8], 2014 | NS | NS | NS | NS | ||
| Biondi et al[9], 2018 | > 60 mo | 45 mo | 0.519 | NS | NS | |
| Bracale et al[10], 2021 | 72% | 71% | 0.41 | 71% | 75% | 0.34 |
| Eom et al[11], 2018 | 73.3% | 51.1% | 0.005 | 62.8% | 49.9% | 0.145 |
| Feng et al[12], 2015 | NS | NS | NS | NS | ||
| Wang et al[13], 2021 | 63.3% | 50% | 0.215 | 60% | 33.3% | 0.019 |
| Xue et al[14], 2018 | 70% | 74% | > 0.05 | NS | NS | |
| Kang et al[15], 2021 | 74.2% | 73.4% | > 0.05 | 66.3% | 60.2% | 0.023 |
| Kano et al[16], 2019 | NS | NS | 80% | 58.7% | 0.037 | |
| Lin et al[17], 20221 | Eastern: 60.1%. Western: 57.3% | Eastern: 49.3%. Western: 39.5% | Eastern: 0.02. Western: 0.11 | NS | NS | |
| Marino et al[18], 2021 | 50 mo | 35 mo | > 0.05 | 48 mo | > 0.05 | |
| Molina et al[19], 2013 | 39.01% | 34.05% | ||||
| Pardo et al[20], 2020 | 41.6% | 38.6% | 0.089 | NS | NS | |
| Wang et al[21], 2019 | 58.7% | 30.9% | 0.008 | NS | NS | |
| Wang et al[22], 2021 | 52 mo | 26.4 mo | < 0.001 | NS2 | NS2 | |
| Wu et al[23], 2019 | NS | NS | NS | NS | ||
| Xu et al[24], 2021 | 72.29% | 36.22% | < 0.001 | 58.53% | 30.87% | < 0.001 |
| Zhao et al[25], 2017 | 17.9 mo | 17.4 mo | > 0.05 | 16.1 mo | 15.8 mo | > 0.05 |
1
All patients received neoadjuvant chemotherapy; adjuvant chemotherapy (first column) and non-adjuvant chemotherapy groups (second column) were compared in two independent (an eastern and a western) cohorts.
2
Not stated for neoadjuvant chemotherapy vs upfront surgery. But nCRT (chemoradio-) significantly better than nCT (chemo-) (P = 0.014).
NAT: Neoadjuvant chemotherapy; US: Upfront surgery; NS: Not stated.